Please login to the form below

Not currently logged in
Email:
Password:

Mundipharma appoints Paul Medeiros head of corporate and business development

He joins from AVI BioPharma and will lead Mundipharma's corporate growth across Europe

Paul Medeiros - MundipharmaAVI BioPharma's Paul Medeiros has joined Mundipharma as head of corporate and business development.

Medeiros will also join the executive leadership team at the UK-based group, which controls Napp in the UK and has associated companies in 32 other European countries.

His role will be to extend and expand areas for growth within this European network of companies.

“Paul's deep experience and network in the pharma industry, combined with his entrepreneurial mind-set and nuanced understanding of the business, will be essential for Mundipharma's continued growth,” said Antony Mattessich, regional director at Mundipharma Europe.

Medeiros was most recently senior VP and chief business officer at AVI BioPharma, a company focused on the development of RNA-based therapeutics for rare diseases.

Other roles in his 19-year career in the biopharma industry include VP, global licensing and strategic alliances for Schering-Plough, as well as several positions in sales and marketing at Merck & Co.

He has been involved with licensing and strategic partnering initiatives in specialist therapy areas, as well as technology acquisitions.

9th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics